STEMI合并CTO患者慢性完全闭塞血运重建的长期影响
EXPLORE随机试验纳入302例STEMI成功直接PCI后合并CTO患者,随机分入CTO-PCI或CTO-No PCI。中位随访3.9年,两组MACE无显著差异(13.5% vs 12.3%,HR 1.03,95%CI 0.54-1.98;P=0.93),CTO-PCI组心源性死亡更常见(6.0% vs 1.0%,P=0.02),1年左室功能无差异,但CTO-PCI组1年无心绞痛比例更高(94% vs 87%,P=0.03)。
要点
- STEMI合并CTO患者中,CTO-PCI未降低长期MACE风险。
- CTO-PCI组心源性死亡发生率高于CTO-No PCI组(6.0% vs 1.0%,P=0.02)。
- CTO-PCI组1年无心绞痛比例更高(94% vs 87%,P=0.03)。
核心结论
- 在STEMI合并CTO患者中,与CTO-No PCI相比,CTO-PCI未减少长期MACE。
- 两组1年左室功能无差异,但CTO-PCI组1年无心绞痛患者更多,需进一步研究。
研究设计与样本
- EXPLORE为多中心随机试验,纳入302例STEMI成功直接PCI后合并CTO的患者,随机分入CTO-PCI或CTO-No PCI组。
主要发现
- 中位长期随访3.9(2.1-5.0)年,MACE两组无显著差异(13.5% vs 12.3%,HR 1.03,95%CI 0.54-1.98;P=0.93)。
- 心源性死亡CTO-PCI组更常见(6.0% vs 1.0%,P=0.02),全因死亡无差异(12.9% vs 6.2%,HR 2.07,95%CI 0.84-5.14;P=0.11)。
- 1年左室功能(LVEF和LVEDV)两组无差异。
- 1年无心绞痛患者比例CTO-PCI组更高(94% vs 87%,P=0.03)。
临床怎么用
- 对于STEMI成功直接PCI后合并CTO的患者,CTO-PCI不应常规用于降低长期MACE。
- CTO-PCI可能改善1年心绞痛症状,但需权衡心源性死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: During primary percutaneous coronary intervention (PCI), a concurrent chronic total occlusion (CTO) is found in 10% of patients with ST-elevation myocardial infarction (STEMI). Long-term benefits of CTO-PCI have been suggested; however, randomised data are lacking. Our aim was to determine mid-term and long-term clinical outcome of CTO-PCI versus CTO-No PCI in patients with STEMI with a concurrent CTO. METHODS: The Evaluating Xience and left ventricular function in PCI on occlusiOns afteR STEMI (EXPLORE) was a multicentre randomised trial that included 302 patients with STEMI after successful primary PCI with a concurrent CTO. Patients were randomised to either CTO-PCI or CTO-No PCI. The primary end point of the current study was occurrence of major adverse cardiac events (MACE): cardiac death, coronary artery bypass grafting and MI. Other end points were 1-year left ventricular function (LVF); LV-ejection fraction and LV end-diastolic volume and angina status. RESULTS: The median long-term follow-up was 3.9 (2.1-5.0) years. MACE was not significantly different between both arms (13.5% vs 12.3%, HR 1.03, 95% CI 0.54 to 1.98; P=0.93). Cardiac death was more frequent in the CTO-PCI arm (6.0% vs 1.0%, P=0.02) with no difference in all-cause mortality (12.9% vs 6.2%, HR 2.07, 95% CI 0.84 to 5.14; P=0.11). One-year LVF did not differ between both arms. However, there were more patients with freedom of angina in the CTO-PCI arm at 1 year (94% vs 87%, P=0.03). CONCLUSIONS: In this randomised trial involving patients with STEMI with a concurrent CTO, CTO-PCI was not associated with a reduction in long-term MACE compared to CTO-No PCI. One-year LVF was comparable between both treatment arms. The finding that there were more patients with freedom of angina after CTO-PCI at 1-year follow-up needs further investigation. CLINICAL TRIAL REGISTRATION: EXPLORE trial number NTR1108 www.trialregister.nl.
引用
- Elias J, van Dongen IM, Råmunddal T, et al. Long-term impact of chronic total occlusion recanalisation in patients with ST-elevation myocardial infarction. Heart. 2018. PMID: 29463612. doi:10.1136/heartjnl-2017-312698
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。